US indexes open mixed, pharmaceutical stocks climb: Morning Brief

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 103 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 58%
  • Publisher: 63%

Madison Mills News

Brad Smith,Nvidia,Market Capitalization

On today's episode of Morning Brief, hosts Brad Smith and Madison Mills analyze the market open and break down the biggest stories of the trading week. The...

) to reclaim the top spot. Moor Insights & Strategy founder, CEO, and chief analyst Patrick Moorhead emphasizes that Nvidia's continued dominance hinges on"then this whole gravy train comes to a screeching halt."" investors should consider trimming some of their gains in these areas and reallocating into sectors like industrials, energy, and healthcare.

In addition, it's S and P rebalance day with the tectonic shift in apple versus in video holdings and video has been setting records for options activity and all in all.

And that is because you do tend to see a little bit of an opportunity to sell off and some of the biggest players in the stock market heading into a triple which day. And we do need to be very careful and look for what I call the precursors of something that could pull back. So what they're doing is they're enabling companies like H Pe Dell Technologies and pure storage and Lenovo to build that out.This is what it was all about.And it's interesting in your notes to us, you explained that this is a private cloud play how bullish of a signal is that for the chip sector in general, but specifically here for NVIDIA.

Yeah, some of the earlier data center uh chips that NVIDIA had, they might sell for 5 $10,000 a piece.Uh It's probably over 1000% gross margin, but the longevity here, so you've got co two levels of competition first. But anyway, all these things considered Patrick, it's been one of the most overcrowded or de facto as Goldman Sachs has called it A I trades here.

And we see, keep seeing positive news coming out from NVIDIA with its partners, Patrick Moorhead, who was the more insights and strategy founder, Ceo and chief analyst, Patrick.Sarepta shares surging after receiving expanded us approval from the FDA for its muscular dystrophy drug Yahoo Finance's Angelique Kani has all the details on this one.

And this is coming from Gilead seeing some really positive results from early trials with regards to an HIV drug.It's a twice yearly shot, uh has proven 100% efficacious in women in a study, a late stage study in Africa that's for women and adolescent girls. We've got the analyst behind it in this hour and stay tuned for our 10 a.m. hour of catalysts where we'll bring you a day in the life of Boston fed President Susan Collins, you won't want to miss it.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 47. in ERROR

Coin Coin Latest News, Coin Coin Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Bullish S&P 500 calls, weak China industrial output: Morning BriefOn today's episode of Morning Brief, Yahoo Finance's Seana Smith and Madison Mills cover some of the biggest stories as the holiday-shortened trading week...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »